151 lines
45 KiB
Text
151 lines
45 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-part">
|
|
<meta name="ncbi_acc" content="NBK23229">
|
|
<meta name="ncbi_domain" content="micad">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK23229/?report=reader">
|
|
<meta name="ncbi_pagename" content="[O-methyl-11C]2-(4-(4-(2-Methoxyphenyl)piperazin-1-yl)butyl)-4-methyl-1,2,4-triazine-3,5(2H,4H)dione - Molecular Imaging and Contrast Agent Database (MICAD) - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="chapter">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>[O-methyl-11C]2-(4-(4-(2-Methoxyphenyl)piperazin-1-yl)butyl)-4-methyl-1,2,4-triazine-3,5(2H,4H)dione - Molecular Imaging and Contrast Agent Database (MICAD) - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="auto">
|
|
<meta name="jr-prev-unit" content="/books/n/micad/PD153035-11C/?report=reader">
|
|
<meta name="jr-next-unit" content="/books/n/micad/MPT11C/?report=reader">
|
|
<meta name="bk-toc-url" content="/books/n/micad/?report=toc">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE">
|
|
<meta name="citation_inbook_title" content="Molecular Imaging and Contrast Agent Database (MICAD) [Internet]">
|
|
<meta name="citation_title" content="[O-methyl-11C]2-(4-(4-(2-Methoxyphenyl)piperazin-1-yl)butyl)-4-methyl-1,2,4-triazine-3,5(2H,4H)dione">
|
|
<meta name="citation_publisher" content="National Center for Biotechnology Information (US)">
|
|
<meta name="citation_date" content="2012/06/20">
|
|
<meta name="citation_author" content="Kam Leung">
|
|
<meta name="citation_pmid" content="20641432">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK23229/">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="[O-methyl-11C]2-(4-(4-(2-Methoxyphenyl)piperazin-1-yl)butyl)-4-methyl-1,2,4-triazine-3,5(2H,4H)dione">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="National Center for Biotechnology Information (US)">
|
|
<meta name="DC.Contributor" content="Kam Leung">
|
|
<meta name="DC.Date" content="2012/06/20">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK23229/">
|
|
<meta name="description" content="Hydroxytryptamine (5-HT), commonly known as serotonin, has diverse physiological roles as a neurotransmitter in the central nervous system (1). 5-HT is involved in regulation and modulation of sleep, affective and personality behaviors, and pain. It also is a regulator of smooth muscle function and platelet aggregation. The brain cortical 5-HT system has been implicated in several neuropsychiatric disorders, including major depression, anxiety, schizophrenia, and obsessive-compulsive disorder (2, 3). The effects of 5-HT are mediated by as many as seven classes of receptor populations (5-HT1 to 5-HT7), many of which include several subtypes (4). There are five receptor subtypes within the G-protein–coupled 5-HT1 receptor family: 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, and 5-HT1F.">
|
|
<meta name="og:title" content="[O-methyl-11C]2-(4-(4-(2-Methoxyphenyl)piperazin-1-yl)butyl)-4-methyl-1,2,4-triazine-3,5(2H,4H)dione">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:description" content="Hydroxytryptamine (5-HT), commonly known as serotonin, has diverse physiological roles as a neurotransmitter in the central nervous system (1). 5-HT is involved in regulation and modulation of sleep, affective and personality behaviors, and pain. It also is a regulator of smooth muscle function and platelet aggregation. The brain cortical 5-HT system has been implicated in several neuropsychiatric disorders, including major depression, anxiety, schizophrenia, and obsessive-compulsive disorder (2, 3). The effects of 5-HT are mediated by as many as seven classes of receptor populations (5-HT1 to 5-HT7), many of which include several subtypes (4). There are five receptor subtypes within the G-protein–coupled 5-HT1 receptor family: 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, and 5-HT1F.">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK23229/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-micad-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/micad/MMP11C/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK23229/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8E955A7D6421210000000000BB00AE.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK23229/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"><div class="head"><a href="/books/n/micad/PD153035-11C/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="body"><div class="t">[O-methyl-11C]2-(4-(4-(2-Methoxyphenyl)piperazin-1-yl)butyl)-4-methyl-1,2,4-triazine-3,5(2H,4H)dione</div><div class="j">Molecular Imaging and Contrast Agent Database (MICAD) [Internet]</div></div><div class="tail"><a href="/books/n/micad/MPT11C/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-rtoc-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK23229/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK23229/&text=%5BO-methyl-11C%5D2-(4-(4-(2-Methoxyphenyl)piperazin-1-yl)butyl)-4-methyl-1%2C2%2C4-triazine-3%2C5(2H%2C4H)dione"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-rtoc-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Table of Content</div></div><div class="cnt lol f1"><a href="/books/n/micad/?report=reader">Title Information</a><a href="/books/n/micad/toc/?report=reader">Table of Contents Page</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK23229/?report=classic">Switch to classic view</a><a href="/books/NBK23229/pdf/Bookshelf_NBK23229.pdf">PDF (148K)</a><a href="/books/NBK23229/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK23229%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8E955A7D6421210000000000BB00AE.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><div class="fm-sec"><h1 id="_NBK23229_"><span class="title" itemprop="name">[O-<i>methyl</i>-<sup>11</sup>C]2-(4-(4-(2-Methoxyphenyl)piperazin-1-yl)butyl)-4-methyl-1,2,4-triazine-3,5(2<i>H</i>,4<i>H</i>)dione</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">[<sup>11</sup>C]MMP (CUMI-101)</div><p class="contribs">Leung K.</p><p class="fm-aai"><a href="#_NBK23229_pubdet_">Publication Details</a></p></div></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figMMP11CTncchemicalnameomethyl11c244"><a href="/books/NBK23229/table/MMP11C.T.nc_chemical_nameomethyl11c244/?report=objectonly" target="object" title="Table" class="img_link icnblk_img" rid-ob="figobMMP11CTncchemicalnameomethyl11c244"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="MMP11C.T.nc_chemical_nameomethyl11c244"><a href="/books/NBK23229/table/MMP11C.T.nc_chemical_nameomethyl11c244/?report=objectonly" target="object" rid-ob="figobMMP11CTncchemicalnameomethyl11c244">Table</a></h4><p class="float-caption no_bottom_margin">
|
|
|
|
<i>In vitro</i>
|
|
|
|
|
|
Non-human primates
|
|
</p></div></div><div id="MMP11C.Background"><h2 id="_MMP11C_Background_">Background</h2><p>[<a href="/entrez/query.fcgi?cmd=PureSearch&db=pubmed&details_term=CUMI-101" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>Hydroxytryptamine (5-HT), commonly known as serotonin, has diverse physiological roles as a neurotransmitter in the central nervous system (<a class="bibr" href="#MMP11C.REF.1" rid="MMP11C.REF.1">1</a>). 5-HT is involved in regulation and modulation of sleep, affective and personality behaviors, and pain. It also is a regulator of smooth muscle function and platelet aggregation. The brain cortical 5-HT system has been implicated in several neuropsychiatric disorders, including major depression, anxiety, schizophrenia, and obsessive-compulsive disorder (<a class="bibr" href="#MMP11C.REF.2" rid="MMP11C.REF.2 MMP11C.REF.3">2, 3</a>). The effects of 5-HT are mediated by as many as seven classes of receptor populations (5-HT<sub>1</sub> to 5-HT<sub>7</sub>), many of which include several subtypes (<a class="bibr" href="#MMP11C.REF.4" rid="MMP11C.REF.4">4</a>). There are five receptor subtypes within the G-protein–coupled 5-HT<sub>1</sub> receptor family: 5-HT<sub>1A</sub>, 5-HT<sub>1B</sub>, 5-HT<sub>1D</sub>, 5-HT<sub>1E</sub>, and 5-HT<sub>1F</sub>.</p><p>5-HT<sub>1A</sub> receptors are abundantly present in the hippocampus, entorhinal cortex, frontal cortex, raphe nucleus, and septum; the lowest densities are observed in the basal ganglia, substantia nigra, and cerebellum (<a class="bibr" href="#MMP11C.REF.5" rid="MMP11C.REF.5">5</a>). Some thalamic and hypothalamic nuclei have intermediate densities. 5-HT<sub>1A</sub> receptors are involved in the mediation of emotion and the function of the hypothalamus. 5-HT<sub>1A</sub> receptors are implicated in anxiety, depression, hallucinogenic behavior, motion sickness, and eating disorders (<a class="bibr" href="#MMP11C.REF.6" rid="MMP11C.REF.6">6</a>). Thus, there is a need for selective ligands to investigate the pharmacological role of 5-HT<sub>1A</sub> receptors.</p><p>There have been several studies to develop specific 5-HT<sub>1A</sub> radioligands [<a href="/entrez/query.fcgi?cmd=PureSearch&db=pubmed&details_term=5-HT1a%5BAll%20Fields%5D%20AND%20imaging%5BAll%20Fields%5D" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>] such as <a href="/books/NBK23263/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">[<i>carbonyl</i>-<sup>11</sup>C]WAY 100635</a>, <a href="/books/NBK23137/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">[<sup>18</sup>F]FPWAY</a>, and <a href="/books/NBK23391/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">[<sup>18</sup>F]MPPF</a> for positron emission tomography (PET) imaging. However, none of these antagonists distinguishes between the high- and low-affinity states of the 5-HT<sub>1A</sub> receptors. The high-affinity state of the receptor is coupled to G-proteins, which mediate the functions of cells by providing intracellular signals. 2-(4-(4-(2-Methoxyphenyl)piperazin-1-yl)butyl)-4-methyl-1,2,4-triazine-3,5(2<i>H</i>,4<i>H</i>)dione (MMP) was reported to be a potent agonist of 5-HT<sub>1A</sub> receptors (<i>K</i><sub>i</sub> = 0.15 nM) (<a class="bibr" href="#MMP11C.REF.7" rid="MMP11C.REF.7">7</a>). This led to the development of [O-<i>methyl</i>-<sup>11</sup>C]2-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butyl)-4-methyl-1,2,4-triazine-3,5(2<i>H</i>,4<i>H</i>)dione ([<sup>11</sup>C]MMP, also known as [<sup>11</sup>C]CUMI-101) as a useful tool for <i>in vivo</i> PET imaging of the 5-HT<sub>1A</sub> receptor.</p><div id="MMP11C.Related_Resource_Links"><h3>Related Resource Links:</h3><ul><li class="half_rhythm"><div>Chapters in MICAD (<a href="/sites/entrez?db=Books&cmd=Search&term=5-HT1A+AND+micad%5bbook%5d&doptcmdl=TOCView&log%24=booksrch&bname=micad" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">5-HT<sub>1</sub><sub>A</sub></a>)</div></li><li class="half_rhythm"><div>Gene information in NCBI (<a href="/gene/3350" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">5-HT<sub>1</sub><sub>A</sub></a>)</div></li><li class="half_rhythm"><div>Articles in Online Mendelian Inheritance in Man (OMIM) (<a href="/omim/109760" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">5-HT<sub>1</sub><sub>A</sub></a>)</div></li><li class="half_rhythm"><div>Clinical trials (<a href="http://www.clinicaltrials.gov/ct2/results?term=5-HT1A" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">5-HT<sub>1</sub><sub>A</sub></a>)</div></li><li class="half_rhythm"><div>Drug information in Food and Drug Administration (<a href="http://google2.fda.gov/search?q=5-HT1a&client=FDAgov&site=FDAgov&lr=&proxystylesheet=FDAgov&output=xml_no_dtd&getfields=*&x=8&y=1" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">5-HT<sub>1</sub><sub>A</sub></a>)</div></li></ul></div></div><div id="MMP11C.Synthesis"><h2 id="_MMP11C_Synthesis_">Synthesis</h2><p>[<a href="/entrez/query.fcgi?cmd=PureSearch&db=pubmed&details_term=CUMI-101%20and%20synthesis" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>The radiosynthesis of [<sup>11</sup>C]MMP, reported by Kumar et al. (<a class="bibr" href="#MMP11C.REF.7" rid="MMP11C.REF.7">7</a>), involved standard <sup>11</sup>C-methylation of the corresponding desmethyl precursor 2-(4-(4-(2-hydroxyphenyl)piperazin-1-yl)butyl)-4-methyl-1,2,4-triazine-3,5-(2<i>H</i>,4<i>H</i>)-dione with [<sup>11</sup>C]CH<sub>3</sub>OTf in acetone in the presence of NaOH. The reported overall radiochemical yield of the radiosynthesis was 30 ± 5% at the end of synthesis (EOS), the specific radioactivity was 96 ± 19 TBq/mmol (2,600 ± 500 Ci/mmol), and the radiochemical purity was >98%. The total synthesis time was 30 min at EOS.</p></div><div id="MMP11C.In_Vitro_Studies_Testing_in_Cells"><h2 id="_MMP11C_In_Vitro_Studies_Testing_in_Cells_"><i>In Vitro</i> Studies: Testing in Cells and Tissues</h2><p>[<a href="/entrez/query.fcgi?cmd=PureSearch&db=pubmed&details_term=CUMI-101%20and%20in%20vitro" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>Kumar et al. (<a class="bibr" href="#MMP11C.REF.7" rid="MMP11C.REF.7">7</a>) performed <i>in vitro</i> competition binding studies with [<sup>3</sup>H]8-OH-DPAT in bovine hippocampus membranes. MMP had a <i>K</i><sub>i</sub> of 0.15 ± 0.05 nM. The affinity of MMP for various biogenic amines, brain receptors, and transporters was determined to be >45 times lower than that of MMP. Agonist properties of MMP on 5-HT<sub>1A</sub> receptors were evaluated using [<sup>35</sup>S]-labeled guanosine gamma thio-phosphate ([<sup>35</sup>S]GTPγS) binding in membranes of Chinese hamster ovary (CHO) cells stably expressing the human 5-HT<sub>1A</sub> receptors. MMP produced a dose-dependent increase in [<sup>35</sup>S]GTPγS binding. Maximal MMP-stimulated [<sup>35</sup>S]GTPγS binding was 80% of that seen with 5-HT. The maximum binding fraction for MMP (0.10 nM) was comparable to that for 5-HT (0.56 nM). There was a measurable free fraction of [<sup>11</sup>C]MMP in baboon (59%) and human (37%) plasma.</p></div><div id="MMP11C.Animal_Studies"><h2 id="_MMP11C_Animal_Studies_">Animal Studies</h2><div id="MMP11C.Rodents"><h3>Rodents</h3><p>[<a href="/entrez/query.fcgi?cmd=PureSearch&db=pubmed&details_term=CUMI-101%20and%20rodentia" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>No publication is currently available.</p></div><div id="MMP11C.Other_NonPrimate_Mammals"><h3>Other Non-Primate Mammals</h3><p>[<a href="/entrez/query.fcgi?cmd=PureSearch&db=pubmed&details_term=CUMI-101%20and%20%28dog%20or%20pig%20or%20sheep%20or%20rabbit%29" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>No publication is currently available.</p></div><div id="MMP11C.NonHuman_Primates"><h3>Non-Human Primates</h3><p>[<a href="/entrez/query.fcgi?cmd=PureSearch&db=pubmed&details_term=CUMI-101%20and%20nonhuman%20primate" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>PET imaging was used to study radioactivity accumulation in baboon brains after intravenous injection of 185 MBq (5 mCi) of [<sup>11</sup>C]MMP (<a class="bibr" href="#MMP11C.REF.7" rid="MMP11C.REF.7">7</a>). Various brain regions exhibited rapid accumulation in 3–13 min with gradual decreases thereafter. [<sup>11</sup>C]MMP PET images (up to 120 min after injection) displayed radioactivity concentrations (tissue/cerebellum ratio) that followed a rank order: the hippocampus (6.25), insular cortex (5.25) cingulate gyrus (4.75), prefrontal cortex (4.0), amygdala (3.75), raphe nucleus (3.0), thalamus (2.0), and cerebellum (1.0) at 105 min. Pretreatment with the antagonist WAY 100635 (0.25 mg/kg) or the agonist 8-OH-DPAT (2 mg/kg) 30 min prior to the injection of [<sup>11</sup>C]MMP markedly reduced the radioactivity by ~70% in the hippocampus, cingulate gyrus and prefrontal cortex. There was a minor blockade effect in the cerebellum. After injection of [<sup>11</sup>C]MMP, 84%, 43%, 32%, and 24% of the total plasma radioactivity was intact at 4, 30, 60, and 90 min, respectively. Only hydrophilic metabolites were detected.</p><p>Milak et al. (<a class="bibr" href="#MMP11C.REF.8" rid="MMP11C.REF.8">8</a>) performed [<sup>11</sup>C]CUMI-101PET scans in the brain of two male baboons. Scanning time of 100 min was adequate and that for the region-of-interest analysis, the likelihood estimation in graphical analysis (LEGA) model provided the best results. The median test–retest percentage difference for binding potential (BP<sub>F</sub>) was 11.15% ± 4.82% across all regions. Pre-administration of WAY100635 and 8-OH-DPAT resulted in 87% and 76% average reductions in BP<sub>F</sub> values across all regions of interests, respectively. All metabolites were more polar than <sup>11</sup>C-CUMI-101, and no significant change in metabolites was observed in the blocking studies. The free fraction in the plasma was 59% ± 3%.</p></div></div><div id="MMP11C.Human_Studies"><h2 id="_MMP11C_Human_Studies_">Human Studies</h2><p>[<a href="/entrez/query.fcgi?cmd=PureSearch&db=pubmed&details_term=CUMI-101%20and%20human" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>Milak et al. (<a class="bibr" href="#MMP11C.REF.9" rid="MMP11C.REF.9">9</a>) performed [<sup>11</sup>C]CUMI-101 PET brain scans of seven human volunteers. Scanning time of 120 min was found to be adequate for the region-of-interest analysis. The LEGA model provided the best results with the median test–retest percentage difference for BP<sub>F</sub> values was 9.9% ± 5.6% across all regions. The free fraction in the plasma was 30% ± 3%. The BP<sub>F</sub> values for entorhinal cortex, hippocampus, temporal lobe, amygdala, insular cortex, cingulate, prefrontal cortex, raphe, and occipital lobe were 32.62, 31.66, 28.61, 25.50, 21.20, 18.48, 13.69, 12.42, and 9.70 mL/cm<sup>3</sup>, respectively.</p><p>Hines et al. (<a class="bibr" href="#MMP11C.REF.10" rid="MMP11C.REF.10">10</a>) performed PET imaging studies to determine biodistribution and dosimetry of 428 ± 84 MBq (11.56 ± 2.27 mCi, 5.0 ± 1.0 nmol) [<sup>11</sup>C]CUMI-101 in nine healthy volunteers. The brain had high accumulation (~11% of injected dose (ID)) at 10 min. Although liver had the highest uptake (~35% ID at 120 min), excretion of radioactivity was not visible in gall bladder or intestine during the scanning session. Organs with the highest radiation doses were the pancreas (32.0 µSv/MBq, 118.4 mrem/mCi), liver (18.4 µSv/MBq, 68.1 mrem/mCi), and spleen (14.5 µSv/MBq, 53.7 mrem/mCi). The effective dose for <sup>11</sup>C-CUMI-101 was 5.3 ± 0.5 µSv/MBq (19.5 ± 2.2 mrem/mCi).</p></div><div id="MMP11C.NIH_Support"><h2 id="_MMP11C_NIH_Support_">NIH Support</h2><p>P50 MH62185, R21 MH077161, K08 MH76258, MH62185,</p></div><div id="MMP11C.References"><h2 id="_MMP11C_References_">References</h2><dl class="temp-labeled-list"><dl class="bkr_refwrap"><dt>1.</dt><dd><div class="bk_ref" id="MMP11C.REF.1">Lucki I.
|
|
<em>The spectrum of behaviors influenced by serotonin.</em>
|
|
<span><span class="ref-journal">Biol Psychiatry. </span>1998;<span class="ref-vol">44</span>(3):151–62.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/9693387" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9693387</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>2.</dt><dd><div class="bk_ref" id="MMP11C.REF.2">Fletcher A., Cliffe I.A., Dourish C.T.
|
|
<em>Silent 5-HT1A receptor antagonists: utility as research tools and therapeutic agents.</em>
|
|
<span><span class="ref-journal">Trends Pharmacol Sci. </span>1993;<span class="ref-vol">14</span>(12):41–8.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/8122313" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8122313</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>3.</dt><dd><div class="bk_ref" id="MMP11C.REF.3">Hoyer D., Clarke D.E., Fozard J.R., Hartig P.R., Martin G.R., Mylecharane E.J., Saxena P.R., Humphrey P.P.
|
|
<em>International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin).</em>
|
|
<span><span class="ref-journal">Pharmacol Rev. </span>1994;<span class="ref-vol">46</span>(2):157–203.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/7938165" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7938165</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>4.</dt><dd><div class="bk_ref" id="MMP11C.REF.4">Lanfumey L., Hamon M.
|
|
<em>5-HT1 receptors.</em>
|
|
<span><span class="ref-journal">Curr Drug Targets CNS Neurol Disord. </span>2004;<span class="ref-vol">3</span>(1):1–10.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/14965240" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 14965240</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>5.</dt><dd><div class="bk_ref" id="MMP11C.REF.5">Pazos A., Probst A., Palacios J.M.
|
|
<em>Serotonin receptors in the human brain--III. Autoradiographic mapping of serotonin-1 receptors.</em>
|
|
<span><span class="ref-journal">Neuroscience. </span>1987;<span class="ref-vol">21</span>(1):97–122.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/2955249" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2955249</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>6.</dt><dd><div class="bk_ref" id="MMP11C.REF.6">Cowen P.J.
|
|
<em>Psychopharmacology of 5-HT(1A) receptors.</em>
|
|
<span><span class="ref-journal">Nucl Med Biol. </span>2000;<span class="ref-vol">27</span>(5):437–9.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/10962247" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10962247</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>7.</dt><dd><div class="bk_ref" id="MMP11C.REF.7">Kumar J.S., Prabhakaran J., Majo V.J., Milak M.S., Hsiung S.C., Tamir H., Simpson N.R., Van Heertum R.L., Mann J.J., Parsey R.V.
|
|
<em>Synthesis and in vivo evaluation of a novel 5-HT(1A) receptor agonist radioligand [O-methyl- (11)C]2-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butyl)-4-methyl-1,2,4-triazi ne-3,5(2H,4H)dione in nonhuman primates.</em>
|
|
<span><span class="ref-journal">Eur J Nucl Med Mol Imaging. </span>2007;<span class="ref-vol">34</span>(7):1050–60.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17221184" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17221184</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>8.</dt><dd><div class="bk_ref" id="MMP11C.REF.8">Milak M.S., Severance A.J., Ogden R.T., Prabhakaran J., Kumar J.S., Majo V.J., Mann J.J., Parsey R.V.
|
|
<em>Modeling considerations for 11C-CUMI-101, an agonist radiotracer for imaging serotonin 1A receptor in vivo with PET.</em>
|
|
<span><span class="ref-journal">J Nucl Med. </span>2008;<span class="ref-vol">49</span>(4):587–96.</span> [<a href="/pmc/articles/PMC3580231/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3580231</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18344443" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18344443</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>9.</dt><dd><div class="bk_ref" id="MMP11C.REF.9">Milak M.S., DeLorenzo C., Zanderigo F., Prabhakaran J., Kumar J.S., Majo V.J., Mann J.J., Parsey R.V.
|
|
<em>In vivo quantification of human serotonin 1A receptor using 11C-CUMI-101, an agonist PET radiotracer.</em>
|
|
<span><span class="ref-journal">J Nucl Med. </span>2010;<span class="ref-vol">51</span>(12):1892–900.</span> [<a href="/pmc/articles/PMC3856257/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3856257</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21098796" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21098796</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>10.</dt><dd><div class="bk_ref" id="MMP11C.REF.10">Hines C.S., Liow J.S., Zanotti-Fregonara P., Hirvonen J., Morse C., Pike V.W., Innis R.B.
|
|
<em>Human biodistribution and dosimetry of (1)(1)C-CUMI-101, an agonist radioligand for serotonin-1a receptors in brain.</em>
|
|
<span><span class="ref-journal">PLoS One. </span>2011;<span class="ref-vol">6</span>(9):e25309.</span> [<a href="/pmc/articles/PMC3181260/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3181260</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21980419" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21980419</span></a>]</div></dd></dl></dl></div><div id="bk_toc_contnr"></div></div></div><div class="fm-sec"><h2 id="_NBK23229_pubdet_">Publication Details</h2><h3>Author Information and Affiliations</h3><div class="contrib half_rhythm"><span itemprop="author">Kam Leung</span>, PhD<div class="affiliation small">National Center for Biotechnology Information, NLM, NIH<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="vog.hin.mln.ibcn@DACIM" class="oemail">vog.hin.mln.ibcn@DACIM</a></div></div><div class="small">Corresponding author.</div></div><h3>Publication History</h3><p class="small">Created: <span itemprop="datePublished">September 4, 2007</span>; Last Update: <span itemprop="dateModified">June 20, 2012</span>.</p><h3>Copyright</h3><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div></div><h3>Publisher</h3><p><a href="http://www.ncbi.nlm.nih.gov/" ref="pagearea=page-banner&targetsite=external&targetcat=link&targettype=publisher">National Center for Biotechnology Information (US)</a>, Bethesda (MD)</p><h3>NLM Citation</h3><p>Leung K. [O-methyl-11C]2-(4-(4-(2-Methoxyphenyl)piperazin-1-yl)butyl)-4-methyl-1,2,4-triazine-3,5(2H,4H)dione. 2007 Sep 4 [Updated 2012 Jun 20]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013. <span class="bk_cite_avail"></span></p></div><div class="small-screen-prev"><a href="/books/n/micad/PD153035-11C/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="small-screen-next"><a href="/books/n/micad/MPT11C/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></article><article data-type="table-wrap" id="figobMMP11CTncchemicalnameomethyl11c244"><div id="MMP11C.T.nc_chemical_nameomethyl11c244" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK23229/table/MMP11C.T.nc_chemical_nameomethyl11c244/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__MMP11C.T.nc_chemical_nameomethyl11c244_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Chemical name:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">[O-<i>methyl</i>-<sup>11</sup>C]2-(4-(4-(2-Methoxyphenyl)piperazin-1-yl)butyl)-4-methyl-1,2,4-triazine-3,5(2<i>H</i>,4<i>H</i>)dione</td><td rowspan="9" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/26719624" title="View this structure in PubChem" class="img_link" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&sid=26719624" alt="image 26719624 in the ncbi pubchem database" /></a>
|
|
</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Abbreviated name:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">[<sup>11</sup>C]MMP</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Synonym:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">[<sup>11</sup>C]CUMI-101</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Agent category:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Compound</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Target:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5-HT<sub>1A</sub> serotonin receptor</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Target category:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Receptor</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Method of detection:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Positron emission tomography (PET)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Source of signal:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><sup>11</sup>C</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Activation:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Studies:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul class="simple-list"><li class="half_rhythm"><div>
|
|
<img alt="Checkbox" src="/corehtml/pmc/css/bookshelf/2.26/img/studies.checkbox.png" />
|
|
<i>In vitro</i>
|
|
|
|
</div></li><li class="half_rhythm"><div>
|
|
<img alt="Checkbox" src="/corehtml/pmc/css/bookshelf/2.26/img/studies.checkbox.png" /> Non-human primates
|
|
</div></li><li class="half_rhythm"><div>
|
|
<img alt="Checkbox" src="/corehtml/pmc/css/bookshelf/2.26/img/studies.checkbox.png" /> Humans
|
|
</div></li></ul>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Click on the above structure for additional information in <a href="http://pubchem.ncbi.nlm.nih.gov/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubChem</a>.</td></tr></tbody></table></div></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal107 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|